Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

Company to Hold Conference Call on Monday, December 10, 2007

NEW HAVEN, Conn., Dec. 6 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that preliminary data from its pivotal Phase II trial of Cloretazine(R) (VNP40101M) in elderly patients with de novo acute myelogenous leukemia (AML) would be presented in a poster at the 2007 American Society of Hematology Annual Meeting in Atlanta, Georgia on Saturday, December 8, 2007.

The poster presentation (#71-1) will be at the Georgia World Conference Center, Hall B4, from 9:00 a.m. to 7:30 p.m. Poster authors will be available from 5:30 p.m. to 7:30 p.m. at the poster. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on Saturday, December 8, 2007 at 9:00 a.m. Eastern Time.

A press release related to the poster will be issued on Monday, December 10, 2007 at 7:30 a.m. Eastern Time. The Company also announced that it would hold a conference call to discuss the poster on Monday, December 10, 2007. The call will begin at 9:00 a.m. Eastern Time.

To participate in the conference call, please dial (866) 356-4123 in the U.S. ((617) 597-5393 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 16444471.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to a
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
(Date:7/29/2014)...  Novation, a VHA and UHC company, today ... features that automate key health care supply chain ... Association.  The new and enhanced ... Value Analysis, Item Master and Formulary – are ... most critical challenges brought on by health care ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5
... Pharmaceuticals (Nasdaq: ENDP ) will announce its third ... host a conference call and webcast at 10:00 a.m. ET ... P. Holveck, president and CEO of Endo, Julie McHugh, chief ... Alan Levin, executive vice president and chief financial officer, and ...
... FUJIFILM Medical Systems U.S.A., Inc. is pleased to announce ... flat panel detector (FPD). This addition to the FDR D-EVO ... vendor to provide a 17 x 17 inch wireless, flat ... solutions for nearly any general radiology exam is proven by ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2Fujifilm Expands FDR D-EVO™ Wireless Product Line With New 17x17 Inch Detector 2Fujifilm Expands FDR D-EVO™ Wireless Product Line With New 17x17 Inch Detector 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 Many people complain ... thing they do each morning is put on glasses to ... These same individuals also may be dissatisfied with their ... , Cataracts may cause difficulty driving, especially at night ... follow or find one’s golf ball, see the TV, sew ...
(Date:7/29/2014)... LA (PRWEB) July 29, 2014 Historically, ... across the United States usually celebrated throughout that time ... though, those summer days now mark the start of ... crashes involving teen drivers. In 2012 nearly 1.000 ... the period from Memorial Day to Labor Day. , ...
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... July 29, 2014 Summer is here, and that ... enjoying a hike, swimming in a pool or laying out on ... fleas and ticks. The Puppy Store is here to help pet ... months. , It’s almost impossible to completely keep fleas and ticks ... minimize the chances of their pets coming into contact with fleas ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Protect Dogs From Fleas and Ticks During the Summer 2
... New web-based research has quantified the attractiveness of the ... features of one woman into 243 variations with differing ... widths. Then more than 34,000 people judged the attractiveness ... the same in all of the photos, researchers found ...
... Old Republic International Corporation (NYSE: ORI ... the payment of the regular quarterly cash dividend of 17 ... March 13, 2009 to shareholders of record on March 4, ... rate initially approved for the second quarter of 2008. ...
... as Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... prevention services, has signed an affiliation agreement with ... group based in Singapore and a subsidiary of ... medicine programs throughout Asia. Under the agreement, ParkwayHealth ...
... 274 adults with intellectual disabilities currently receiving funding ... , Washington, DC(February 23, 2009)The Supports Intensity ... for people with intellectual disability based on individual ... tool, unlike adaptive behavior instruments or other measures ...
... at the UCSF-Gladstone Institute for Virology and Immunology Center ... development of the next generation of HIV/AIDS researchers and ... published in the American Journal for Public Health ... of the AJPH website, the program focuses on overcoming ...
... Abbott ( NYSE: ABT ),today announced that it has ... now a wholly owned subsidiary of Abbott and has been,renamed ... acquisition of AMO enhances and strengthens Abbott,s diverse mix of,medical ... large and,growing eye care market. Abbott Medical Optics holds ...
Cached Medicine News:Health News:Plastic and reconstructive surgery ... in brief 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Supports Intensity Scale is effective for identifying needs in people with intellectual disability 2Health News:Effective mentoring critical to HIV/AIDS research efforts 2Health News:Abbott Completes Acquisition of Advanced Medical Optics 2
... is a three-part differential control assayed for all ... Series, T Series, AcT/AcT diff/AcT diff2, MD Series ... 1700, and 1800; Danam Datacell18, Datacell 18MS/18MS Plus, ... PLUS and I-1600; the ABX Micros 60, and ...
... Plus Retics is a 5-part differential control ... the Coulter GENS, STKS, LH 750/LH 755, ... automated and manual reticulocyte values for all ... reticulocyte percentages vary and are within clinically ...
... is a gene expression ... the risk of metastasis ... It is based on ... the Netherlands Cancer Institute ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: